GCM
ABVX

Ghisallo Capital Management’s Abivax ABVX Stock Holding History

Ghisallo Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-60,000
Closed -$642K – 116
2023
Q4 		$642K Buy
+60,000
New +$612K 0.07% 104

Other funds holding ABVX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Ghisallo Capital Management's ABVX Position: Q1 2024 in Review

Ghisallo Capital Management sold out of Abivax (ABVX) in Q1 2024, closing a stake of 60,000 shares — an estimated $642K sold.

Ghisallo Capital Management first reported a position in ABVX in Q4 2023 and held it in 1 quarter. The position peaked at $642K in Q4 2023. 36 funds tracked by Wall St. Rank hold ABVX as of Q1 2024.

  • Ghisallo Capital Management reported no remaining Abivax position as of Q1 2024 after selling out during the quarter.
  • Ghisallo Capital Management sold 60,000 Abivax shares in Q1 2024, an estimated $642K.
  • Ghisallo Capital Management first reported a position in Abivax in Q4 2023 and held it in 1 quarter.
  • Ghisallo Capital Management's Abivax position peaked at $642K in Q4 2023.
  • 36 funds tracked by Wall St. Rank held Abivax as of Q1 2024.

Based on Ghisallo Capital Management's 13F filing for Q1 2024, filed 15 May 2024.